# LAVA Therapeutics N.V.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lava-therapeutics-n-v

- Industry: Biotechnology
- Headquarters: Utrecht, Netherlands
- Website: www.lavatherapeutics.com
- Total disclosed funding: $103M
- Latest round: Series C (Sep 17, 2020)
- Investors on record: 8

## About

LAVA Therapeutics N.V., based in the Netherlands, focuses on developing innovative cancer therapies utilizing its Gammabody® platform to engage gamma delta T cells for enhanced immune response against tumors.Founded in 2016 and headquartered in Utrecht, Netherlands, LAVA Therapeutics N.V. specializes in cancer immunotherapy. The company has conducted 6 deals and recently completed an IPO, raising USD 100.50 mn, which represents the total amount raised to date. Stephen Hurly serves as CEO.LAVA Therapeutics specializes in innovative cancer therapies through its Gammabody® platform, which produces bispecific gamma delta T cell engagers. These therapeutics activate V?9Vd2 T cells, enhancing tumor recognition and selective cell killing. The primary end users are cancer patients, while healthcare providers administer these treatments, primarily targeting markets in North America and Europe.In 2023, LAVA Therapeutics reported revenue of USD 6.77 mn, with an EBITDA of -USD 43.88 mn. The company generates revenue through collaborations with research institutions and pharmaceutical companies, focusing on licensing agreements and milestone payments.LAVA Therapeutics is strategically positioned for future growth through the development of new products in its Gammabody® platform, which are anticipated to launch within the next few years. The company plans to expand its market reach into North America and Europe by 2025. Recent funding from Kinled Holding will support these initiatives, enhancing research and development efforts and facilitating entry into new markets.

## Funding rounds

- Series C, Sep 17, 2020, $84M — Versant Ventures, Gilde Healthcare, Ysios Capital Partners, Sanofi Ventures, Redmile Group, Novo Holdings, MRL Ventures Fund, Pureos Bioventures
- Series A, May 23, 2018, $19M — Versant Ventures, Gilde Healthcare, MRL Ventures Fund

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series C
- Gilde Healthcare (https://capitalatlas.ai/funds/gilde-healthcare) — Series A, Series C
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A, Series C
- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series C
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series C
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C
- Novo Holdings — Series C
- Pureos Bioventures (https://capitalatlas.ai/funds/pureos-bioventures) — Series C